SMMT Incurs Wider-Than-Expected Q4 Loss, Pipeline Progress in Focus

Core Insights - Summit Therapeutics (SMMT) reported a fourth-quarter 2025 loss per share of 29 cents, which is wider than the Zacks Consensus Estimate of 22 cents and a significant increase from a loss of 8 cents per share in the same period last year [1][6] - The company did not record any revenues in 2025 as it currently lacks a marketed product [1][6] - For the full year 2025, SMMT recorded a net loss of $1.44 per share, compared to a net loss of 31 cents in 2024 [4] Financial Performance - Adjusted research and development (R&D) expenses reached $102 million, reflecting a 117% increase year over year, primarily due to higher clinical study costs [2] - Adjusted general and administrative expenses increased by 50.6% year over year to $11.3 million, driven by costs associated with developing infrastructure for ivonescimab [2] - As of December 31, 2025, the company had cash, cash equivalents, and short-term investments totaling $713.4 million, up from $238.6 million as of September 30, 2025 [3] Pipeline Developments - The lead program in SMMT's pipeline is ivonescimab, a dual PD-1/VEGF inhibitor being evaluated in late-stage studies for non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) [7] - The FDA accepted the biologics license application (BLA) for ivonescimab, with a decision expected by November 14, 2026 [8] - The company is currently enrolling patients in three late-stage studies for ivonescimab, including HARMONi-3 and HARMONi-7 for NSCLC, and HARMONi-GI3 for CRC [9][10] Collaborations and Future Plans - In January 2026, SMMT announced a collaboration with GSK to evaluate ivonescimab in combination with GSK's investigational drug across multiple solid tumor settings [11] - Patient dosing for this collaboration is expected to commence in mid-2026 [11]